As befits this struggling economy, each of the Big Three in diagnostic imaging sounded downbeat in their 2008 year-end financial assessments. Siemens AG saw declining orders for imaging equipment in the US; Royal Philips Electronics NV experienced a 6% reduction in new order revenue in the fourth quarter, "largely if not totally driven by North America"; and GE Healthcare , a division of General Electric Co., reported that domestic order revenue was down nearly 30% in the quarter. As reported in The Gray Sheet, those cautionary comments "closely coincided with the release of multiple reports detailing hospitals’ reluctance to fund expensive capital projects." (See "Diagnostics Imaging Sector Hit By Hospitals' Dwindling Access to Capital," The Gray Sheet, February 2, 2009 Also see "Diagnostics Imaging Sector Hit By Hospitals’ Dwindling Access To Capital" - Medtech Insight, 2 February, 2009..)
Amersham Little Help to GE Healthcare in This Down Market
As befits this struggling economy, each of the Big Three in diagnostic imaging sounded downbeat in their 2008 year-end financial assessments. But more so than the other two, GE Healthcare focuses on the development of new imaging agents, owing to its acquisition of Amersham in late 2003. Ant that integration has been admittedly slow.
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
More from In Vivo
Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.